The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Current research in elderly, untreated AML: venetoclax combinations
Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, is researching the effect of venetoclax combination therapies in previously untreated elderly acute myeloid leukemia (AML). In this interview, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, she follows on from a discussion of the positive results from her group’s venetoclax/azacitidine trial (NCT02203773) by speaking about a new trial comparing venetoclax/azacitidine with azacitidine alone, as well as a trial exploring the effect of venetoclax with low-dose cytarabine (NCT02287233) in this patient population. Finally, she discusses ventoxlax combinations in relapsed elderly AML, including the combination with idasanutlin or cobimetinib (NCT02670044), highlighting genetic biomarkers which correlate with improved or reduced treatment efficacy in these patients.
